Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q2 2024 Earnings Conference Call July 30, 2024 8:30 AM ET

Company Participants

Ji-Yon Yi - Investor Relations
Sujal Patel - Co-Founder & Chief Executive Officer
Parag Mallick - Co-Founder & Chief Scientist
Anna Mowry - Chief Financial Officer

Conference Call Participants

Matt Sykes - Goldman Sachs
Tycho Peterson - Jefferies
Dan Brennan - TD Cowen

Operator

Good day and thank you for standing by and welcome to Nautilus Q2 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today to Ji-Yon Yi, Investor Relations. Please go ahead.

Ji-Yon Yi

Thank you. Earlier today, Nautilus released financial results for the quarter ended June 30, 2024. If you haven't received this news release or if you'd like to be added to the company's distribution list, please send an e-mail to Investor Relations at nautilus.bio. Joining me today from Nautilus are Sujal Patel, Co-Founder and CEO; Parag Mallick, Co-Founder and Chief Scientist; and Anna Mowry, Chief Financial Officer.

Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled Forward-Looking Statements in the press release Nautilus issued today. Except as required by law, Nautilus disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast, July 30, 2024.

With that, I'll turn the call over to Sujal.

Sujal Patel

Thanks, Jon and welcome to everyone joining our Q2 2024 earnings call. The update that Parag, Anna and I will be sharing with you today is due to the great work of our teams in the Bay Area, Seattle and San Diego. My thanks go out to them for their continued progress against our key scientific and business objectives. I look forward to the day that their work is in the hands of researchers who will leverage our platform to explore important biological questions once thought unanswerable.

The team remains focused on both our development milestones and commercialization goals. Through these and other efforts, we remain motivated by our purpose to revolutionize Proteomics in the name of improving the lives and health of millions of people around the world. Our entire team is motivated by this goal, fully aligned and committed to doing what it takes to make this reality.